Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 13/20 | 0.68 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | CA12 | O43570 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | CA3 | P07451 | 2/20 | 0.41 |
| ▸ | CA4 | P22748 | 2/20 | 0.41 |
| ▸ | CA6 | P23280 | 2/20 | 0.41 |
| ▸ | CA7 | P43166 | 2/20 | 0.41 |
| ▸ | CA9 | Q16790 | 2/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.41 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.41 |
| ▸ | CA5A | P35218 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | ALPL | P05186 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | ALPI | P09923 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | ALPG | P10696 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10208641 | 0.89 | APP (0.64) | APPCYP1A2CA12CA2CA3 | |
| SCHEMBL563769 | 0.86 | APP (0.66) | APPCYP1A2KDM4EMEN1ALDH1A1 | |
| SCHEMBL1094100 | 0.82 | APP (0.59) | APPCYP1A2KDM4EMEN1ALDH1A1 | |
| SCHEMBL6998321 | 0.82 | APP (0.67) | APPCYP1A2KDM4EMEN1ALDH1A1 | |
| SCHEMBL9537836 | 0.82 | APP (0.59) | APPCYP1A2KDM4EMEN1ALDH1A1 | |
| SCHEMBL19831443 | 0.82 | APP (0.59) | APPCYP1A2MEN1POLBMAPT | |
| Water SCHEMBL18894321 | 0.81 | APP (0.58) | APPCYP1A2KDM4EMEN1ALDH1A1 | |
| SCHEMBL4922053 | 0.81 | APP (0.57) | APPCYP1A2 | |
| SCHEMBL8066 | 0.81 | APP (1.00) | APPCYP1A2MEN1POLBKMT2A | |
| Alcohol SCHEMBL6810203 | 0.81 | APP (0.86) | APPCYP1A2MEN1POLBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9670170-B2 | Resorufin derivatives for treatment of oxidative stress disorders | BIOELECTRON TECHNOLOGY CORPORATION (US) | 2017-06-06 | — | — | US | disclosed |
| US-9296712-B2 | Resorufin derivatives for treatment of oxidative stress disorders | EDISON PHARMACEUTICALS, INC. (US) | 2016-03-29 | — | — | US | disclosed |
| US-20160039775-A1 | RESORUFIN DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISORDERS | PTC THERAPEUTICS, INC. | 2016-02-11 | — | — | US | disclosed |
| US-9216974-B2 | Phenoxazine derivatives and methods of use thereof | WASHINGTON UNIVERSITY (US) | 2015-12-22 | — | — | US | disclosed |
| US-9115099-B2 | Phenoxazine derivatives and methods of use thereof | WASHINGTON UNIVERSITY (US) | 2015-08-25 | — | — | US | disclosed |
| US-20150175589-A1 | PHENOXAZINE DERIVATIVES AND METHODS OF USE THEREOF | UNIV WASHINGTON (US) | 2015-06-25 | — | — | US | disclosed |
| US-20140275054-A1 | RESORUFIN DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISORDERS | EDISON PHARMACEUTICALS, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140221647-A1 | PHENOXAZINE DERIVATIVES AND METHODS OF USE THEREOF | WASHINGTON UNIVERSITY | 2014-08-07 | — | — | US | disclosed |
| US-8735575-B2 | Phenoxazine derivatives and methods of use thereof | WASHINGTON UNIVERSITY (US) | 2014-05-27 | — | — | US | disclosed |
| US-20120035359-A1 | PHENOXAZINE DERIVATIVES AND METHODS OF USE THEREOF | THE WASHINGTON UNIVERSITY (US) | 2012-02-09 | — | — | US | disclosed |
| US-20120035359-A1 | PHENOXAZINE DERIVATIVES AND METHODS OF USE THEREOF | THE WASHINGTON UNIVERSITY (US) | 2012-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221647-A1 | PHENOXAZINE DERIVATIVES AND METHODS OF USE THEREOF | PPOX, CYP4Z1, PRDX2 | APP 3242/4885CYP1A2 12/4885CA12 463/4885 |
| US-20150175589-A1 | PHENOXAZINE DERIVATIVES AND METHODS OF USE THEREOF | PPOX, CYP4Z1, PRDX2 | APP 3242/4885CYP1A2 12/4885CA12 463/4885 |
| US-20160039775-A1 | RESORUFIN DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISORDERS | TXNRD2, NDUFAB1, NDUFAF1 | APP 482/4885CYP1A2 1581/4885CA12 4877/4885 |
| US-20120035359-A1 | PHENOXAZINE DERIVATIVES AND METHODS OF USE THEREOF | PPOX, CYP4Z1, PRDX2 | APP 3242/4885CYP1A2 12/4885CA12 463/4885 |
| US-20140275054-A1 | RESORUFIN DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISORDERS | TXNRD2, NDUFAB1, NDUFAF1 | APP 482/4885CYP1A2 1581/4885CA12 4877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.